Helio Genomics and LiverRight have entered a partnership to improve access to early liver cancer detection in the US.
The collaboration combines Helio Genomics’ LiverTrace blood-based test with LiverRight’s network of hepatology professionals, aiming to streamline the process from detection to expert consultation.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
LiverTrace employs AI and machine learning (ML) to analyse blood samples for cancer biomarker detection.
This technology can identify indications of liver cancer prior to tumours becoming visible through ultrasound imaging.
Through this collaboration, individuals who receive LiverTrace outcomes can promptly access hepatologists and hepatology advanced practice providers of LiverRight.
These specialists offer interpretation of test outcomes and, when appropriate, guide patients through further diagnosis and treatment.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLiverTrace is designed for adults considered at risk for liver cancer, including those with previous liver conditions, a family history, or factors associated with lifestyle that elevate their risk.
After a test is ordered, a collection kit is sent to the patient’s home, and a mobile phlebotomist will visit for a blood draw.
Results are said to be typically available within 14 business days and are delivered online.
LiverRight chief medical officer Dr Alexander Lalos said: “When caught early — before the liver tumour is large or has spread — several potentially curative options are available, including liver transplantation. With early-stage diagnosis, five-year survival rates can exceed 70%, sometimes higher depending on the treatment modality.”
Both companies have noted that the partnership is based on a mutual goal of improving liver cancer outcomes by facilitating early identification and connecting patients with specialist care.
Helio’s multi-analyte blood-based platform leverages deep learning and ML for cancer biomarker detection, aiming to support patients and clinicians in responding quickly to liver cancer risks.
